| Name | Title | Contact Details |
|---|---|---|
Geoffrey Parker |
Chief Financial Officer | Profile |
Eric Schmidt |
Chief Financial Officer | Profile |
Debiprasad Roy |
Exec. Director & Head of R&D Technology, Data Science, & Digital Strategy | Profile |
Rafael Amado |
Executive Vice President, Head of R&D and Chief medical Officer | Profile |
Mark Leonard |
VP Process and Product Development | Profile |
Gel-Del is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Enabling the Promise of Advanced Therapies
Founded by Longwood Fund, Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis is employing site-specific conjugation technology to develop highly stable ADCs with enhanced therapeutic indexes. Pyxis is also advancing a diverse portfolio of immunotherapies that target broad immune regulators as well as novel immune checkpoints identified through its immuno-oncology and cold tumor discovery efforts.
Compliance Associates is a Concord, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.